Cornerstone Planning Group
ACAD icon

Cornerstone Planning Group’s Acadia Pharmaceuticals ACAD Stock Holding History

Cornerstone Planning Group’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-26
Closed -$649 – 187
2026
Q2 		$649 Buy
+26
New +$572 ﹤0.01% 1617
2024
Q2 		– Sell
-50
Closed -$853 – 1260
2024
Q1 		$853 Buy
+50
New +$1.24K ﹤0.01% 812

Other funds holding ACAD

Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
State of Alaska Department of Revenue
State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return
Louisiana State Employees Retirement System
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.56B AUM 41.43% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return
Yousif Capital Management
Yousif Capital Management Bloomfield Hills, Michigan $8.87B AUM 34.1% 1-Year Est. Return
Gradient Investments
Gradient Investments Arden Hills, Minnesota $7B AUM 14.85% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Concurrent Investment Advisors
Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return

Cornerstone Planning Group's ACAD Position: Q3 2026 in Review

Cornerstone Planning Group sold out of Acadia Pharmaceuticals (ACAD) in Q3 2026, closing a stake of 26 shares — an estimated $649 sold.

Cornerstone Planning Group first reported a position in ACAD in Q1 2024 and held it in 2 quarters. The position peaked at $853 in Q1 2024. 41 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.

  • Cornerstone Planning Group reported no remaining Acadia Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Cornerstone Planning Group sold 26 Acadia Pharmaceuticals shares in Q3 2026, an estimated $649.
  • Cornerstone Planning Group first reported a position in Acadia Pharmaceuticals in Q1 2024 and held it in 2 quarters.
  • Cornerstone Planning Group's Acadia Pharmaceuticals position peaked at $853 in Q1 2024.
  • 41 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.

Based on Cornerstone Planning Group's 13F filing for Q3 2026, filed 16 Oct 2026.